Drugs.com - New Drug Approvals

FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease

HORSHAM, Pa. (March 20, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and...

Mar 24, 2025 - 03:30
 0
FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease
HORSHAM, Pa. (March 20, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and...
Read More

Tags:

Previous Article

Designers of Zadig & Voltaire Have a New Paris Apartment

Next Article

Nationals guarantee that Coalition can lower power prices ‘in the short term’ me...

Related Posts

U.S. FDA Approves Expanded Label for Astellas' Izervay (avacincaptad pegol intravitreal solution) for Geographic Atrophy

U.S. FDA Approves Expanded Label for Astellas' Izervay ...

Feb 13, 2025  0

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to ...

Feb 17, 2025  0

FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves Vtama (tapinarof) Cream for the Treatment ...

Feb 9, 2025  0